Wolverine
WOLV · 20 mg blend · daily
SCIENCE • STRENGTH • LONGEVITY
Before you draw anything. Every figure in this document assumes a 10 mg + 10 mg blend vial reconstituted with 2.0 mL of bacteriostatic water. Change either number and every unit measurement here changes with it. Confirm the milligram strengths printed on your vial first.
Wolverine pairs the two most-studied repair peptides in one vial. BPC-157 is linked to blood vessel formation at injury sites and tissue protection, with most preclinical work covering tendon, ligament, and gut tissue. TB-500 acts on actin, the structural protein that lets cells migrate, and works systemically rather than at the injection site. The two are combined because their mechanisms are complementary rather than overlapping.
RECONSTITUTION
| Parameter | Value |
|---|---|
| Vial | 20 mg total — BPC-157 10 mg + TB-500 10 mg, 1:1 by weight |
| Bacteriostatic water | 2.0 mL |
| Concentration | 5 mg/mL of each peptide (10 mg/mL total blend) |
| Conversion | 10 units = 500 mcg of each · 1 unit = 50 mcg of each |
| Route | Subcutaneous |
| Vial coverage | 20 draws at the standard amount |
| Reconstituted storage | 2–8 °C, 1–2 weeks. TB-500 is the limiting component. |
| Lyophilized storage | −20 °C, 12+ months |
- Let the vial and the bacteriostatic water reach room temperature.
- Swab both stoppers with alcohol and let them dry.
- Draw 2.0 mL of bacteriostatic water into a sterile syringe.
- Aim the stream at the inside wall of the glass, never directly at the powder.
- Roll gently for 30 to 60 seconds until fully dissolved. Never shake.
- Confirm the solution is clear before use.
- Label with product, concentration, and date, then refrigerate.
DOSING SCHEDULE
| Phase | Amount (each peptide) | Units | Frequency | Duration |
|---|---|---|---|---|
| Loading | 500 mcg | 10 | Daily | Weeks 1–4 |
| Maintenance | 250 mcg | 5 | Daily | Weeks 5–8 |
Amounts refer to each peptide, not the combined total — a 10-unit draw delivers 500 mcg of BPC-157 and 500 mcg of TB-500. Run 4 to 8 weeks, then stop.
What a fixed 1:1 blend can and cannot do. The two compounds are dosed on very different schedules when bought separately — BPC-157 daily in micrograms, TB-500 twice weekly in milligrams. In a blend they can only move together, so the ratio is a compromise. At 10 units daily the BPC-157 amount lands squarely in its standard range, while the TB-500 works out to roughly 3.5 mg per week against 5 to 10 mg in a standalone injury protocol. That is the trade for the convenience of one vial and one injection. Where TB-500 specifically needs to run high, separate vials are the better structure.
Notes
- Inject subcutaneously near the area of interest where practical. BPC-157 is commonly placed near the site; TB-500 works systemically either way, so proximity costs nothing.
- Daily dosing with no scheduled off-day during the loading phase.
- One vial covers 20 days at the loading amount, which is inside the 1–2 week stability window only if you reconstitute in two halves. Consider splitting the powder or accepting TB-500 drop-off in the back half.
- Rotate within the general area rather than using one exact spot.
- Reported effects are mild and infrequent — injection-site irritation is the most common, with short-term fatigue in the first week or two.
- Never combine with another compound in the same syringe.
Relationship to GLOW 70
GLOW 70 contains the same two peptides alongside GHK-Cu, but at roughly 330 mcg of each per daily draw and weighted heavily toward GHK-Cu. Wolverine drops the copper component and raises both repair peptides. Run one or the other for a given goal rather than both — GLOW for skin quality and general remodeling, Wolverine when the target is soft tissue.
CAUTIONS
- Active cancer or a strong cancer history. Both compounds promote angiogenesis, and new blood vessel growth is what a tumor requires to expand. This is the principal caution and it applies twice over in this blend.
- Active retinal vascular disease or other conditions sensitive to angiogenic signaling.
- Pregnancy or breastfeeding — no safety data exists.
- Both compounds are prohibited by WADA at all times, in and out of competition.
- BPC-157 was removed from the FDA bulk-substance list for compounding, which is a change in regulatory posture worth being aware of.
Supplies
- U-100 insulin syringes, 0.3 mL / 30-unit. Half-unit gradations matter at these draw volumes.
- Bacteriostatic water, 10 mL bottle.
- Alcohol prep pads and a sharps container.
- Sterile empty vials if splitting the reconstitution to stay inside the TB-500 window.
Record keeping
Log the date, units drawn, and site for every injection, alongside any symptoms. This catches gradual dose drift, and if something does go wrong it identifies exactly which step it started on.